Macitentan denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for macitentan are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Macitentan as Not FDA-Approved — And Why You Can Appeal

Macitentan is an FDA-approved medication with a defined approved indication. A denial characterizing it as not FDA-approved is a factual error that is directly refutable by reference to the FDA's public records and the drug's prescribing label. This type of denial is among the most straightforward to overturn, because the appeal relies on objective regulatory documentation rather than clinical judgment alone.

The most likely explanation for this denial is either an administrative error (wrong drug code, wrong indication coded), or Aetna applying the "not FDA-approved" basis to an off-label use of macitentan. If the prescribing physician is using macitentan for its FDA-approved indication, the denial should be reversed. If it involves an off-label use, the appeal strategy shifts to demonstrating that the off-label use is supported by substantial clinical evidence and recognized in the applicable guideline organization's recommendations.

## Why This Denial Is Appealable

If macitentan is being prescribed for its FDA-approved indication (PAH), you can directly refute the denial by submitting the FDA-approved prescribing label and confirming the coded indication matches the approval. If the use is off-label, federal law and most insurer policies do not automatically exclude coverage for off-label uses supported by evidence — Aetna's own clinical policy bulletin typically addresses this standard.

## Federal Appeal Framework

• Internal appeal: File within the timeframe in the denial letter. Standard: 60 days. Expedited: 72 hours for urgent situations.
• External review (ACA §2719): Available after a final internal denial, generally within four months. For not-FDA-approved denials, external IRO review specifically assesses whether the denial meets the evidentiary standard.
• Expedited external review: Available for urgent cases alongside expedited internal review.
• ERISA §503: Employer-sponsored plans must conduct a full-and-fair review of all submitted evidence.

## Documentation to Gather

• FDA-approved prescribing label for macitentan: confirming the approved indication
• Diagnosis confirmation: specialist records confirming the diagnosis for which macitentan is prescribed
• Prescriber medical-necessity letter: confirming the indication matches the FDA approval (or, for off-label use, explaining the evidence base and clinical rationale)
• Applicable guideline organization reference: if off-label, a general reference to the guideline body that includes this use in its recommendations
• Aetna's coverage policy: identify the specific not-FDA-approved criterion and address it directly

## Criteria-Mapping Structure

Your appeal should open by establishing the FDA approval status with a direct citation to the prescribing label, then confirm that the prescribed use matches the approved indication. If the use is off-label, follow with a structured argument addressing Aetna's evidentiary standard for off-label coverage. Attach all referenced records as labeled exhibits.